They achieve for the first time the disappearance of pancreatic cancer in mice

They achieve for the first time the disappearance of pancreatic cancer in mice

A team led by Spanish researchers has for the first time in mice completely eliminate pancreatic cancer, an advance that paves the way for the development of effective therapies against this type of tumor, which has a very high mortality rate

A team led by Spanish researchersIt has managed for the first time in mice completely eliminate pancreatic cancer, a move that paves the way for the development of effective therapies against this type of tumor, which has a very high mortality rate.

The team, led by Dr. Mariano Barbacid, head of the AXA Group of the National Center for cancer research (CNIO), has made this discovery by combining theElimination of two molecular targets(called EGFR and c-RAF) related to the gene responsible for the initiation of more than 95 per cent of this type of tumors (the oncogene KRAS).

Barbacid has insisted, in an appearance before the press to publicize the results, in whichIt is "a first step",that must be further investigated, that the application of this type of therapy is not available for humans within a period of at least five years, and that it therefore does not work for patients who currently suffer from this type of cancer.Pancreatic cancer, one of the most aggressive that exist, affects in Spain about 8,000 people each year, and have a survival rate at five years from diagnosis, only 5 per cent.

"Ductal adenocarcinoma of pancreas" is one of the cancers more resistant to current treatments, and now his cure is limited to those cases in which the tumor is very localized and can be removed surgically, which represents less than u n 10 percent of patients.It is the third leading cause of death, in United Statesbehind only lung and colon cancer, and its mortality rate outperforms already in Spain of the breast cancer.

To present the results of the investigation appeared before the media, in addition to Barbacid,Dr. Alfredo CarratoHead of the Oncology service of the Hospital Ramón and Cajal in Madrid and director of the Instituto Ramon y Cajal in health research; and Dr. Marta Puyol, Director of research of the Spanish Association against Cancer.

Doctor Carrato underlined thatevery day "we beat cancer land" but has lamented that "it is not the case of pancreatic cancer",He has been referred to as a "health emergency of the first order", and has regretted that the diagnosis comes late and the median survival rate is very low. At work it has also been proven thatthe two molecular targets inhibition prevents the proliferation of nine of every ten human pancreatic tumors,Although this progress has been tested with experimental models.

The authors of the research have been explained that the success of these experimental therapiesIt is not a guarantee that it will work in patients,but that activity is considered as a first step essential to the development of clinical trials. In Spain the incidence of pancreatic cancer is considered "average" to be similar to the rest of the world (approximately 6.6 cases per 100,000 inhabitants per year in men and in women 3.9), but with a very significant rise in recent decades.

The research has been used a new generation of genetically modified mice to induce the same mutations that are responsible for the majority of this type of tumors in humans.The result was that a percentage of tumors not only stopped growing but that in a few weeks it disappeared completely,a therapeutic effect that had there been never so far in any experimental model, and it was further noted that this was achieved with very low levels of toxicity (a dermatitis very easily controllable).

Doctor Carrato has regretted thatthe diagnosis of pancreatic cancer is "very late", and has impacted on the importance of screening for asymptomatic patients (when you have a family history), personalized treatment, and the need to concentrate resources on very specialized centers."Our challenge is to gain ground to disease;We get in our patients what Mariano Barbacid team has already achieved in mice", has asserted Alfredo Carrato.

Barbacid, who has insisted that such findings should not arouse "false hopes" among those who today suffer from pancreatic cancer, has pointed out that the problem of cancer is not kill tumor cells, but get it without causing a high toxicity.This discovery has managed the regression of these tumors with a "minimal" toxicitysaid the doctor Barbacid, who pointed out that the findings open the door to use in the future of new drugs that circumvent "poisons" which are currently used to combat the disease.

The challenge is to move from animal testing to humanAccording to doctor Carrato, who concluded that the pancreas, although it's a tumor bit often, is the most lethal of all, and in 95 percent of cases is forecast is "disastrous".

Source:cadenaser.com